- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-1-1-mer
- Ligands
- 25 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 29 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.29: 2 residues within 4Å:- Chain A: N.308, E.309
Ligand excluded by PLIPNAG.30: 7 residues within 4Å:- Chain A: N.332, S.333, T.341, N.355, S.357
- Ligands: NAG-NAG.11, NAG-NAG.11
Ligand excluded by PLIPNAG.31: 2 residues within 4Å:- Chain A: N.361
- Ligands: NAG-NAG.11
Ligand excluded by PLIPNAG.32: 3 residues within 4Å:- Chain A: N.103, G.114, R.140
Ligand excluded by PLIPNAG.33: 2 residues within 4Å:- Chain A: N.107, D.294
Ligand excluded by PLIPNAG.34: 2 residues within 4Å:- Chain B: N.100, S.102
Ligand excluded by PLIPNAG.35: 2 residues within 4Å:- Chain B: S.125, N.126
Ligand excluded by PLIPNAG.36: 5 residues within 4Å:- Chain B: D.113, N.114
- Chain G: Q.1, Y.26, R.97
Ligand excluded by PLIPNAG.37: 5 residues within 4Å:- Chain B: R.106, N.107
- Chain H: R.53, A.54, S.55
Ligand excluded by PLIPNAG.38: 3 residues within 4Å:- Chain C: E.57, N.58
- Chain D: S.17
Ligand excluded by PLIPNAG.39: 6 residues within 4Å:- Chain C: N.332, S.333, T.341, N.355
- Ligands: NAG-NAG.17, NAG-NAG.17
Ligand excluded by PLIPNAG.40: 2 residues within 4Å:- Chain C: N.103, R.140
Ligand excluded by PLIPNAG.41: 3 residues within 4Å:- Chain C: N.204, T.206, S.244
Ligand excluded by PLIPNAG.42: 7 residues within 4Å:- Chain C: Q.263, N.265, N.301, V.302, S.303, R.412
- Ligands: NAG-NAG.21
Ligand excluded by PLIPNAG.43: 4 residues within 4Å:- Chain C: S.357, N.361
- Ligands: NAG-NAG.17, NAG-NAG.17
Ligand excluded by PLIPNAG.44: 3 residues within 4Å:- Chain C: K.304, N.308, W.364
Ligand excluded by PLIPNAG.45: 4 residues within 4Å:- Chain D: N.100, S.102, W.103, I.130
Ligand excluded by PLIPNAG.46: 5 residues within 4Å:- Chain D: K.122, E.123, S.125, N.126, Y.127
Ligand excluded by PLIPNAG.47: 4 residues within 4Å:- Chain E: E.57, N.58
- Chain F: G.16, S.17
Ligand excluded by PLIPNAG.48: 3 residues within 4Å:- Chain C: R.278
- Chain E: R.162, N.167
Ligand excluded by PLIPNAG.49: 5 residues within 4Å:- Chain E: N.204, T.206, S.244, I.247, H.321
Ligand excluded by PLIPNAG.50: 2 residues within 4Å:- Chain E: N.271, I.292
Ligand excluded by PLIPNAG.51: 1 residues within 4Å:- Chain E: N.324
Ligand excluded by PLIPNAG.52: 8 residues within 4Å:- Chain E: N.332, S.333, T.341, N.355, S.357
- Ligands: NAG-NAG.27, NAG-NAG.27, NAG.53
Ligand excluded by PLIPNAG.53: 4 residues within 4Å:- Chain E: S.357, N.361
- Ligands: NAG-NAG.27, NAG.52
Ligand excluded by PLIPNAG.54: 5 residues within 4Å:- Chain E: N.103, R.113, G.114, R.140, Y.161
Ligand excluded by PLIPNAG.55: 4 residues within 4Å:- Chain E: Q.263, N.265, R.412
- Ligands: NAG-NAG.26
Ligand excluded by PLIPNAG.56: 3 residues within 4Å:- Chain F: N.100, S.102, Y.127
Ligand excluded by PLIPNAG.57: 4 residues within 4Å:- Chain F: E.123, S.125, N.126, Y.127
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Pedenko, B. et al., Structure of LN02-ML85 Fab in complex with DS-SOSIP. To Be Published
- Release Date
- 2025-09-24
- Peptides
- Envelope glycoprotein gp160: ACE
Envelope glycoprotein gp160: BDF
Heavy chain Fab of antibody LN02-ML85: G
Light chain of antibody LN02-ML85: H - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AC
CE
EB
BD
DF
FG
HH
L
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-1-1-mer
- Ligands
- 25 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 29 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Pedenko, B. et al., Structure of LN02-ML85 Fab in complex with DS-SOSIP. To Be Published
- Release Date
- 2025-09-24
- Peptides
- Envelope glycoprotein gp160: ACE
Envelope glycoprotein gp160: BDF
Heavy chain Fab of antibody LN02-ML85: G
Light chain of antibody LN02-ML85: H - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AC
CE
EB
BD
DF
FG
HH
L